Gold nanocrystals are being investigated as an experimental approach to neurodegenerative disease, including multiple sclerosis (MS) and Parkinson’s disease (PD). The best-known programme involves CNM-Au8, an engineered pharmaceutical suspension of faceted gold nanocrystals developed by Clene Nanomedicine.
To understand how specialised nanocrystal studies differ from evidence for consumer colloidal gold, see our colloidal gold benefits and research overview.
The research is scientifically interesting, but it is important to describe it accurately. CNM-Au8 remains investigational and is not an approved treatment for MS or Parkinson’s disease. Human studies have shown evidence that the formulation can engage brain-energy targets. In MS, a separate Phase 2 study has also produced preliminary efficacy signals. In Parkinson’s disease, however, the published human evidence remains much earlier and has not established clinical benefit.
Just as importantly, CNM-Au8 is not the same product as consumer colloidal gold. Its manufacturing, particle characteristics, dose and clinical development programme are specific to the investigational medicine.
Quick Answer: Are Gold Nanocrystals Proven Treatments for MS or Parkinson’s?
No. CNM-Au8 is an investigational gold nanocrystal medicine. The published REPAIR programme provides evidence of metabolic target engagement in the brain, while the VISIONARY-MS trial provides preliminary Phase 2 efficacy signals in MS. Neither body of evidence establishes CNM-Au8 as an approved or proven treatment for MS or Parkinson’s disease.
The evidence is also different between the two conditions. MS has randomized placebo-controlled Phase 2 data in addition to metabolic imaging studies. Parkinson’s disease currently has a much smaller human evidence base centred on the open-label REPAIR-PD target-engagement study.
What Is CNM-Au8?
CNM-Au8 is a pharmaceutical suspension of clean-surfaced, faceted gold nanocrystals in a buffered liquid. It has been developed to investigate whether catalytic nanocrystals can influence cellular redox reactions, mitochondrial function and energy metabolism in the central nervous system.
This formulation matters because nanoscale materials are highly dependent on their physical and chemical properties. Particle size, shape, surface chemistry, concentration, manufacturing method and route of administration can all affect biological behaviour.
For that reason, results from CNM-Au8 cannot automatically be transferred to another gold nanoparticle preparation or to an ordinary colloidal-gold supplement.
Why Brain Energy Is Being Studied in MS and Parkinson’s
MS and Parkinson’s disease are different disorders, but researchers have investigated mitochondrial dysfunction, oxidative stress and impaired cellular energy metabolism in both.
One molecule of particular interest is NAD+, which participates in redox reactions and cellular energy metabolism. Researchers can examine the relationship between oxidized NAD+ and reduced NADH as one indicator of cellular energetic state.
The REPAIR studies used high-field phosphorus magnetic resonance spectroscopy, or 31P-MRS, to measure energy-related metabolites in living brain tissue. The aim was not to prove symptom improvement. It was to determine whether oral CNM-Au8 could produce a measurable biochemical change in the human brain.
REPAIR-MS and REPAIR-PD: Evidence of Target Engagement
The peer-reviewed REPAIR publication combined data from two small Phase 2 studies: REPAIR-MS and REPAIR-PD. Participants continued their usual treatment while receiving oral CNM-Au8 for at least 12 weeks.
There were 24 evaluable participants with post-baseline scans: 11 with relapsing MS and 13 with idiopathic Parkinson’s disease.
In the prespecified combined analysis, the mean brain NAD+/NADH ratio increased by 10.4% after treatment, with a reported p value of 0.037. This is the strongest basis for saying that CNM-Au8 showed brain target engagement in the combined study population.
However, the distinction between the combined result and the individual disease groups is important. When analysed separately, the direction of change was similar but did not reach conventional statistical significance in either the Parkinson’s cohort or the MS cohort.
| Analysis | What was observed | Interpretation |
|---|---|---|
| Combined MS + PD cohort | NAD+/NADH ratio increased 10.4%, p=0.037 | Evidence of metabolic target engagement in the combined evaluable group |
| Parkinson’s cohort | Directionally increased, p=0.11 | Not statistically significant on its own |
| MS cohort | Directionally increased, p=0.14 | Not statistically significant on its own |
The publication also reported changes in secondary or exploratory energetic measures. These findings support further research into the biological activity of CNM-Au8, but they do not establish that the medicine slows disease progression or improves symptoms.
In REPAIR-MS, the publication also reported that the NAD+/NADH ratio returned toward baseline after a six-week treatment withdrawal, adding support to the interpretation that the observed biochemical change was related to treatment exposure.
Read the peer-reviewed REPAIR publication on PubMed.
Why REPAIR-PD Does Not Prove Parkinson’s Benefit
REPAIR-PD was a small, single-centre pilot study involving 13 participants with Parkinson’s disease. Its main purpose was to assess brain metabolic target engagement using 31P-MRS.
It was not a large randomized trial designed to determine whether CNM-Au8 improves movement, stiffness, quality of life or long-term Parkinson’s progression. The published REPAIR paper therefore should not be presented as proof of functional improvement in Parkinson’s disease.
As of September 2026, Clene’s public pipeline still lists REPAIR-PD as its human Parkinson’s CNM-Au8 study. The company has also reported preclinical Parkinson’s-model work, but preclinical cell or model data are not equivalent to demonstrated clinical benefit in people.
What VISIONARY-MS Adds to the MS Evidence
MS has a broader clinical evidence base because CNM-Au8 was also studied in VISIONARY-MS, a randomized, double-blind, placebo-controlled Phase 2 trial in stable relapsing-remitting MS with chronic optic neuropathy.
The trial planned to enrol 150 participants but stopped early because of COVID-19 operational disruption, enrolling 73. Nearly all participants were receiving background disease-modifying therapy.
According to company-reported Phase 2 results, the modified-intention-to-treat analysis found a least-squares mean difference of 3.13 letters for the primary low-contrast letter-acuity endpoint, with a 95% confidence interval from -0.08 to 6.33 and p=0.056.
Because the trial was under-enrolled, the statistical analysis plan had pre-specified a p<0.10 threshold. Under that plan, the company described the primary endpoint as met. However, the result did not cross the conventional p<0.05 threshold, and the full intention-to-treat analysis was directionally consistent but not statistically significant.
Some secondary modified-MS-Functional-Composite measures were statistically significant in the modified-intention-to-treat analysis, including mean standardized change at p=0.0207. These findings are worth following, but they remain Phase 2 signals from a prematurely stopped trial and require confirmation in a larger study.
What About the Long-Term MS Extension?
Clene has also reported longer-term open-label extension data from VISIONARY-MS, including improvements in low-contrast vision and cognitive processing measures among participants who continued or later received CNM-Au8.
Those observations are scientifically interesting, but an open-label extension has important limitations. There is no continuing blinded placebo comparison over the full extension period, participants who remain in a long-term study can differ from those who do not, and post-hoc biomarker analyses are generally more exploratory than a prospectively powered randomized endpoint.
The long-term results therefore add to the research story but should not be treated as equivalent to independent Phase 3 confirmation.
Safety: What Has Actually Been Reported?
CNM-Au8 was reported as generally well tolerated in the small REPAIR studies and in the VISIONARY-MS Phase 2 programme. Those observations are relevant, but they do not settle the long-term safety question for every population or duration of use.
Small early-phase studies are primarily useful for identifying common or obvious safety problems. Less common adverse effects and long-term risks require larger exposures and continued clinical monitoring.
Where CNM-Au8 Development Stands in 2026
CNM-Au8 remains an investigational therapy. Clene’s current pipeline lists programmes in ALS, MS and Parkinson’s disease.
For MS, the company has reported discussions with the US FDA around a planned Phase 3 programme focused on cognition as an adjunct to standard-of-care therapy. In 2026, Clene said it was incorporating regulatory feedback while finalizing that trial design.
For Parkinson’s disease, Clene’s public pipeline continues to list REPAIR-PD as the relevant human CNM-Au8 study. The evidence base is therefore materially less developed than the MS programme.
Clene’s separate regulatory activity involving a potential New Drug Application in ALS should not be interpreted as approval or efficacy evidence for MS or Parkinson’s disease. Each indication requires its own evidence and regulatory review.
Why This Research Does Not Validate Consumer Colloidal Gold
This is one of the most important distinctions in the entire gold-nanoparticle field.
CNM-Au8 is a controlled investigational nanomedicine with defined manufacturing and clinical dosing. A consumer colloidal-gold product can differ in particle-size distribution, shape, surface chemistry, concentration, aggregation state, excipients and manufacturing method.
Therefore, even if CNM-Au8 eventually proves clinically effective in a neurological disease, that would demonstrate the performance of that formulation in that indication. It would not automatically prove that colloidal gold supplements produce the same effects.
For a broader explanation of this distinction, read Gold Healing’s Gold Nanoparticles Research Library and Colloidal Gold and the Brain: What Does the Science Say?.
How Strong Is the Evidence?
| Evidence | What it shows | What it does not show |
|---|---|---|
| REPAIR-MS + REPAIR-PD | Combined brain metabolic target engagement after 12+ weeks | Does not prove clinical efficacy in either disease |
| REPAIR-PD | Small human metabolic-imaging pilot | No established randomized evidence of Parkinson’s symptom or progression benefit |
| VISIONARY-MS | Randomized Phase 2 efficacy signals in a modified-intention-to-treat analysis | Under-enrolled; primary result did not meet conventional p<0.05 and ITT analysis was not significant |
| VISIONARY-MS extension | Longer-term company-reported vision, cognition and biomarker observations | Open-label extension does not replace blinded Phase 3 confirmation |
| 2026 development status | MS Phase 3 planning/finalization; PD development continues | CNM-Au8 is not an approved MS or PD therapy |
What Researchers Still Need to Show
- Whether the metabolic changes seen in REPAIR consistently translate into meaningful clinical benefit.
- Whether MS efficacy signals can be reproduced in a sufficiently powered confirmatory randomized trial.
- Whether CNM-Au8 can improve clinically important Parkinson’s outcomes in randomized controlled research.
- Whether any benefit is sustained over longer periods and across broader patient populations.
- The long-term safety profile with larger cumulative exposure.
Those questions are exactly why Phase 2 signals should be described as promising research rather than as established treatment effects.
Frequently Asked Questions
Is CNM-Au8 the same as colloidal gold?
No. CNM-Au8 is an engineered investigational gold nanocrystal medicine manufactured for pharmaceutical research. Consumer colloidal-gold products can differ substantially in particle characteristics, concentration, formulation and manufacturing.
Is CNM-Au8 approved for multiple sclerosis?
No. As of September 2026, CNM-Au8 remains investigational. Clene has discussed and is developing a Phase 3 MS programme, but the treatment is not an approved MS therapy.
What did the REPAIR trials actually show?
Across 24 evaluable participants with MS or Parkinson’s disease, the combined analysis found a 10.4% increase in the brain NAD+/NADH ratio after at least 12 weeks of CNM-Au8. The individual MS and Parkinson’s cohorts did not reach conventional statistical significance separately. The study therefore supports target engagement rather than established clinical efficacy.
Did VISIONARY-MS prove that gold nanocrystals treat MS?
No. The Phase 2 trial produced encouraging modified-intention-to-treat signals, but it was stopped early at 73 of 150 planned participants. The primary result had p=0.056, which met the trial’s pre-specified p<0.10 threshold but not the conventional p<0.05 threshold, and the full intention-to-treat analysis was not statistically significant.
Has CNM-Au8 been shown to improve Parkinson’s symptoms?
Not conclusively. The published REPAIR-PD human study was a small target-engagement pilot centred on brain metabolic imaging. It was not a large randomized efficacy trial demonstrating improvement in Parkinson’s symptoms or disease progression.
Do these studies prove that consumer colloidal gold helps neurological disease?
No. Clinical findings from a specific engineered nanomedicine cannot automatically be transferred to a different consumer colloidal-gold formulation.
Scientific Sources
- Robinson AP, et al. Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials. Journal of Nanobiotechnology. 2023. PubMed PMID 38087362.
- REPAIR-PD clinical study record, NCT03815916. ClinicalTrials.gov.
- REPAIR-MS clinical study record, NCT03993171. ClinicalTrials.gov.
- VISIONARY-MS Phase 2 company-reported topline results. Clene, 2022.
- Clene CNM-Au8 clinical pipeline and current study listings. Clene pipeline.
- Clene 2026 development update describing ongoing MS Phase 3 planning. Clene, February 2026.
